Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy
Evidence on the impact of COVID-19 vaccination on symptoms, Health-Related Quality of Life (HRQoL) and Work Productivity and Activity Impairment (WPAI) is scarce. We analyzed associations between bivalent BA.4/5 BNT162b2 (BNT162b2) and these patient-reported outcomes (PROs). Symptomatic US adults te...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/11/1669 |
| _version_ | 1797457547565727744 |
|---|---|
| author | Manuela Di Fusco Xiaowu Sun Laura Anatale-Tardiff Alon Yehoshua Henriette Coetzer Mary B. Alvarez Kristen E. Allen Thomas M. Porter Laura Puzniak Santiago M. C. Lopez Joseph C. Cappelleri |
| author_facet | Manuela Di Fusco Xiaowu Sun Laura Anatale-Tardiff Alon Yehoshua Henriette Coetzer Mary B. Alvarez Kristen E. Allen Thomas M. Porter Laura Puzniak Santiago M. C. Lopez Joseph C. Cappelleri |
| author_sort | Manuela Di Fusco |
| collection | DOAJ |
| description | Evidence on the impact of COVID-19 vaccination on symptoms, Health-Related Quality of Life (HRQoL) and Work Productivity and Activity Impairment (WPAI) is scarce. We analyzed associations between bivalent BA.4/5 BNT162b2 (BNT162b2) and these patient-reported outcomes (PROs). Symptomatic US adults testing positive for SARS-CoV-2 were recruited between 2 March and 18 May 2023 (CT.gov NCT05160636). PROs were assessed using four questionnaires measuring symptoms, HRQoL and WPAI (a CDC-based symptom survey, PROMIS Fatigue, EQ-5D-5L, WPAI-GH), from pre-COVID to Week 4 following infection. Multivariable analysis using mixed models for repeated measures was conducted, adjusting for several covariates. The study included 643 participants: 316 vaccinated with BNT162b2 and 327 unvaccinated/not up-to-date. Mean (SD) age was 46.5 years (15.9), 71.2% were female, 44.2% reported prior infection, 25.7% had ≥1 comorbidity. The BNT162b2 cohort reported fewer acute symptoms through Week 4, especially systemic and respiratory symptoms. All PROs were adversely affected, especially at Week 1; however, at that time point, the BNT162b2 cohort reported better work performance, driven by less absenteeism, and fewer work hours lost. No significant differences were observed for HRQoL COVID-19 negatively impacted patient outcomes. Compared with unvaccinated/not up-to-date participants, those vaccinated with bivalent BA.4/5 BNT162b2 reported fewer and less persistent symptoms and improved work performance. |
| first_indexed | 2024-03-09T16:23:37Z |
| format | Article |
| id | doaj.art-643a6eda5ade4d1bb8f287bfb1621b9f |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T16:23:37Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-643a6eda5ade4d1bb8f287bfb1621b9f2023-11-24T15:10:01ZengMDPI AGVaccines2076-393X2023-10-011111166910.3390/vaccines11111669Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail PharmacyManuela Di Fusco0Xiaowu Sun1Laura Anatale-Tardiff2Alon Yehoshua3Henriette Coetzer4Mary B. Alvarez5Kristen E. Allen6Thomas M. Porter7Laura Puzniak8Santiago M. C. Lopez9Joseph C. Cappelleri10Pfizer, Inc., New York, NY 10001, USACVS Health, Woonsocket, RI 02895, USACVS Health, Woonsocket, RI 02895, USAPfizer, Inc., New York, NY 10001, USACVS Health, Woonsocket, RI 02895, USAPfizer, Inc., New York, NY 10001, USAPfizer, Inc., New York, NY 10001, USAPfizer, Inc., New York, NY 10001, USAPfizer, Inc., New York, NY 10001, USAPfizer, Inc., New York, NY 10001, USAPfizer, Inc., New York, NY 10001, USAEvidence on the impact of COVID-19 vaccination on symptoms, Health-Related Quality of Life (HRQoL) and Work Productivity and Activity Impairment (WPAI) is scarce. We analyzed associations between bivalent BA.4/5 BNT162b2 (BNT162b2) and these patient-reported outcomes (PROs). Symptomatic US adults testing positive for SARS-CoV-2 were recruited between 2 March and 18 May 2023 (CT.gov NCT05160636). PROs were assessed using four questionnaires measuring symptoms, HRQoL and WPAI (a CDC-based symptom survey, PROMIS Fatigue, EQ-5D-5L, WPAI-GH), from pre-COVID to Week 4 following infection. Multivariable analysis using mixed models for repeated measures was conducted, adjusting for several covariates. The study included 643 participants: 316 vaccinated with BNT162b2 and 327 unvaccinated/not up-to-date. Mean (SD) age was 46.5 years (15.9), 71.2% were female, 44.2% reported prior infection, 25.7% had ≥1 comorbidity. The BNT162b2 cohort reported fewer acute symptoms through Week 4, especially systemic and respiratory symptoms. All PROs were adversely affected, especially at Week 1; however, at that time point, the BNT162b2 cohort reported better work performance, driven by less absenteeism, and fewer work hours lost. No significant differences were observed for HRQoL COVID-19 negatively impacted patient outcomes. Compared with unvaccinated/not up-to-date participants, those vaccinated with bivalent BA.4/5 BNT162b2 reported fewer and less persistent symptoms and improved work performance.https://www.mdpi.com/2076-393X/11/11/1669SARS-CoV-2BA.4/5 BNT162b2bivalentCOVID-19COVID-19 symptomsHRQoL |
| spellingShingle | Manuela Di Fusco Xiaowu Sun Laura Anatale-Tardiff Alon Yehoshua Henriette Coetzer Mary B. Alvarez Kristen E. Allen Thomas M. Porter Laura Puzniak Santiago M. C. Lopez Joseph C. Cappelleri Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy Vaccines SARS-CoV-2 BA.4/5 BNT162b2 bivalent COVID-19 COVID-19 symptoms HRQoL |
| title | Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy |
| title_full | Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy |
| title_fullStr | Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy |
| title_full_unstemmed | Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy |
| title_short | Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy |
| title_sort | impact of bivalent ba 4 5 bnt162b2 covid 19 vaccine on acute symptoms quality of life work productivity and activity levels among symptomatic us adults testing positive for sars cov 2 at a national retail pharmacy |
| topic | SARS-CoV-2 BA.4/5 BNT162b2 bivalent COVID-19 COVID-19 symptoms HRQoL |
| url | https://www.mdpi.com/2076-393X/11/11/1669 |
| work_keys_str_mv | AT manueladifusco impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT xiaowusun impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT lauraanataletardiff impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT alonyehoshua impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT henriettecoetzer impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT marybalvarez impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT kristeneallen impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT thomasmporter impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT laurapuzniak impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT santiagomclopez impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy AT josephccappelleri impactofbivalentba45bnt162b2covid19vaccineonacutesymptomsqualityoflifeworkproductivityandactivitylevelsamongsymptomaticusadultstestingpositiveforsarscov2atanationalretailpharmacy |